CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone41-41-561-3277
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.12 million
Profitability
Miscellaneous
Employees188
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Crispr Therapeutics (NASDAQ:CRSP) Frequently Asked Questions
What is Crispr Therapeutics' stock symbol?
Crispr Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."
How were Crispr Therapeutics' earnings last quarter?
Crispr Therapeutics AG (NASDAQ:CRSP) released its quarterly earnings results on Monday, July, 29th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.84. The firm had revenue of $0.32 million for the quarter, compared to analyst estimates of $47.57 million. Crispr Therapeutics had a negative net margin of 15,136.56% and a negative return on equity of 51.49%. The firm's revenue was down 70.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.82) EPS. View Crispr Therapeutics' Earnings History.
When is Crispr Therapeutics' next earnings date?
What price target have analysts set for CRSP?
15 Wall Street analysts have issued twelve-month price targets for Crispr Therapeutics' stock. Their forecasts range from $21.00 to $73.00. On average, they anticipate Crispr Therapeutics' stock price to reach $58.30 in the next twelve months. This suggests a possible upside of 19.3% from the stock's current price. View Analyst Price Targets for Crispr Therapeutics.
What is the consensus analysts' recommendation for Crispr Therapeutics?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crispr Therapeutics in the last year. There are currently 2 sell ratings, 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Crispr Therapeutics.
What are Wall Street analysts saying about Crispr Therapeutics stock?
Here are some recent quotes from research analysts about Crispr Therapeutics stock:
- 1. According to Zacks Investment Research, "CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. " (8/1/2019)
- 2. Needham & Company LLC analysts commented, "Crispr reported 1Q19 financial results yesterday and we spoke w/ mgmt for an update. The company announced last night that regulatory agencies in both the U.S. and Canada have cleared initiation of a Phase 1/2 trial of CTX-110, an allogeneic CAR-T cell therapy in development for CD-19 cancers. Mgmt reiterated guidance for trial initiation in 2Q19. 1/2 trials of CTX-001 continue to enroll pts, although infusion of first pt in latter trial is not expected until mid-2019. Mgmt still aspires to present data from the CTX-001 program at the ASH mtg in Dec 2019, depending on trial progress. Reiterate BUY. Progression of CRISPR-based allogeneic CAR-T program into the clinic later in 2Q19 represents important milestone for the company." (5/1/2019)
- 3. William Blair analysts commented, "CRISPR Therapeutics AG We are initiating coverage on CRISPR Perform rating and $39 fair value estimate. While we acknowledge the innovative nature of the CRISPR/Cas9 discovery and the ease of use and flexibility of the platform as a potential ex vivo and in vivo therapeutic modality, we view the most-progressed indications being targeted—beta-thalassemia and sickle cell with CTX001 in col- laboration with Vertex and allogeneic T-cell therapy for hematological malignancies (acute lymphocytic leukemia [ALL], non-Hodgkin lymphoma [NHL], and multiple myeloma [MM])—as hyper-competitive spaces where the company is behind the leaders in clinical development." (3/13/2019)
Has Crispr Therapeutics been receiving favorable news coverage?
News articles about CRSP stock have been trending positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Crispr Therapeutics earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the immediate future. View News Stories for Crispr Therapeutics.
Are investors shorting Crispr Therapeutics?
Crispr Therapeutics saw a increase in short interest in July. As of July 15th, there was short interest totalling 5,168,300 shares, an increase of 11.5% from the June 15th total of 4,634,600 shares. Based on an average daily trading volume, of 529,400 shares, the short-interest ratio is currently 9.8 days. Approximately 19.6% of the shares of the stock are sold short. View Crispr Therapeutics' Current Options Chain.
Who are some of Crispr Therapeutics' key competitors?
Some companies that are related to Crispr Therapeutics include Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), bluebird bio (BLUE), Adaptive Biotechnologies (ADPT), Repligen (RGEN), Moderna (MRNA), argenx (ARGX), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN) and Halozyme Therapeutics (HALO).
What other stocks do shareholders of Crispr Therapeutics own?
Who are Crispr Therapeutics' key executives?
Crispr Therapeutics' management team includes the folowing people:
- Dr. Rodger Novak, Founder, Chairman & Pres (Age 52)
- Dr. Samarth Kulkarni, CEO & Director (Age 40)
- Mr. Michael John Tomsicek, Chief Financial Officer (Age 53)
- Dr. Tony W. Ho, Head of R&D and Exec. VP
- Dr. N. Anthony Coles Jr., Sr. Advisor (Age 59)
When did Crispr Therapeutics IPO?
(CRSP) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.
Who are Crispr Therapeutics' major shareholders?
Crispr Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (5.15%), Nikko Asset Management Americas Inc. (3.54%), EcoR1 Capital LLC (2.95%), Price T Rowe Associates Inc. MD (1.35%), Cormorant Asset Management LP (1.28%) and Wells Fargo & Company MN (1.10%). Company insiders that own Crispr Therapeutics stock include Aktiengesellschaft Bayer, Bradley J Phd Bolzon, Corp /De/ Celgene, Kurt Von Emster, Lawrence Otto Klein, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Thomas Woiwode, Tyler Dylan-Hyde, Versant Venture Capital V, LP and Vertex Pharmaceuticals (Europe. View Institutional Ownership Trends for Crispr Therapeutics.
Which major investors are selling Crispr Therapeutics stock?
CRSP stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Ontario Teachers Pension Plan Board, Farallon Capital Management LLC, Cormorant Asset Management LP, Global Thematic Partners LLC, Artal Group S.A., Allianz Asset Management GmbH and Bank of America Corp DE. Company insiders that have sold Crispr Therapeutics company stock in the last year include Kurt Von Emster, Lawrence Otto Klein, Rodger Novak and Samarth Kulkarni. View Insider Buying and Selling for Crispr Therapeutics.
Which major investors are buying Crispr Therapeutics stock?
CRSP stock was purchased by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., ARK Investment Management LLC, Price T Rowe Associates Inc. MD, Wells Fargo & Company MN, Balyasny Asset Management LLC, Asymmetry Capital Management L.P., Essex Investment Management Co. LLC and OZ Management LP. Company insiders that have bought Crispr Therapeutics stock in the last two years include Aktiengesellschaft Bayer and Vertex Pharmaceuticals (Europe. View Insider Buying and Selling for Crispr Therapeutics.
How do I buy shares of Crispr Therapeutics?
Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Crispr Therapeutics' stock price today?
One share of CRSP stock can currently be purchased for approximately $48.86.
How big of a company is Crispr Therapeutics?
Crispr Therapeutics has a market capitalization of $2.67 billion and generates $3.12 million in revenue each year. The company earns $-164,980,000.00 in net income (profit) each year or ($3.44) on an earnings per share basis. Crispr Therapeutics employs 188 workers across the globe.View Additional Information About Crispr Therapeutics.
What is Crispr Therapeutics' official website?
How can I contact Crispr Therapeutics?
Crispr Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-41-561-3277 or via email at [email protected]
MarketBeat Community Rating for Crispr Therapeutics (NASDAQ CRSP)
MarketBeat's community ratings are surveys of what our community members think about Crispr Therapeutics and other stocks. Vote "Outperform" if you believe CRSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRSP will underperform the S&P 500 over the long term. You may vote once every thirty days.
